Efficacy

Kisqali (Ribociclib) Efficacy in Treating Breast Cancer

Kisqali (ribociclib) is a targeted therapy medication that has shown efficacy in the treatment of certain types of breast cancer. Specifically, Kisqali is approved for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. Clinical trials have demonstrated that ribociclib, in combination with letrozole, significantly improves progression-free survival compared to letrozole alone. This benefit is observed in postmenopausal women with HR+/HER2- advanced breast cancer.

Several pivotal studies, such as the MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials, have supported the approval and use of Kisqali. These studies have shown that when used in combination with either an aromatase inhibitor or fulvestrant, Kisqali has led to a notable delay in disease progression. The MONALEESA-7 trial specifically addressed premenopausal women and also found that ribociclib, when used with endocrine therapy and ovarian suppression, improved survival outcomes.

Orserdu (Elacestrant) Efficacy in Treating Breast Cancer

Orserdu (elacestrant) is a newer oral selective estrogen receptor degrader (SERD) that has shown promise in the treatment of estrogen receptor-positive (ER+), HER2- advanced or metastatic breast cancer in postmenopausal women or in men. Elacestrant is designed to target and degrade the estrogen receptor, thereby inhibiting the growth of cancer cells that rely on estrogen signals. Clinical trials evaluating the efficacy of Orserdu have demonstrated its potential as a treatment option for patients with advanced breast cancer who have received prior endocrine therapy.

The efficacy of Orserdu was highlighted in the EMERALD phase 3 trial, which showed that elacestrant significantly improved progression-free survival compared to standard endocrine therapies in patients with ER+/HER2- advanced or metastatic breast cancer. The trial included patients who had disease progression on or after one or two lines of endocrine therapy, indicating that Orserdu could be an effective treatment option for patients with advanced disease who have previously been treated with other endocrine therapies. The results of the EMERALD trial are particularly important as they suggest a potential new line of treatment for patients with limited options after standard therapies.